These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 34328006)
1. Complete resolution of chylothorax with ibrutinib in chronic lymphocytic leukemia: a case report. Cheng L; Huang M; Wei J; Xu H; Zhou M; Jiang L Ann Palliat Med; 2022 May; 11(5):1833-1837. PubMed ID: 34328006 [TBL] [Abstract][Full Text] [Related]
2. Complete resolution of chylopericardium after chemotherapy for chronic lymphocytic leukemia. Morris AL; Colbourne T; Kirkpatrick I; Banerji V Curr Oncol; 2019 Oct; 26(5):e696-e699. PubMed ID: 31708663 [TBL] [Abstract][Full Text] [Related]
3. Non hemorrhagic pericardial effusion from ibrutinib İn a patient without comorbidities. Aslan Candır B; Yiğenoğlu TN; Kızıl Çakar M; Dal MS; Altuntaş F J Oncol Pharm Pract; 2022 Jun; 28(4):972-974. PubMed ID: 35006020 [TBL] [Abstract][Full Text] [Related]
4. Ibrutinib in Advanced Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Lower Risk of Hepatitis B Virus Reactivation. Yang S; Zhu R; Li N; Feng Y; Zuo R; Gale RP; Huang X Acta Haematol; 2022; 145(1):54-62. PubMed ID: 34569486 [TBL] [Abstract][Full Text] [Related]
6. Use of Fludarabine for the Treatment of Indolent Lymphoma with Chylothorax. Wild A; Holasová J; Králiková E Klin Onkol; 2018; 31(4):301-304. PubMed ID: 30541315 [TBL] [Abstract][Full Text] [Related]
8. Chylothorax in chronic lymphocytic leukemia patient. Doerr CH; Staats BA; Markovic SN Am J Hematol; 2002 Jul; 70(3):237-40. PubMed ID: 12111770 [TBL] [Abstract][Full Text] [Related]
9. Real-world Prescription Pattern, Discontinuation and Costs of Ibrutinib-Naïve Patients with Chronic Lymphocytic Leukemia: An Italian Healthcare Administrative Database Analysis. Ronconi G; Dondi L; Calabria S; Piccinni C; Pedrini A; Esposito I; Martini N Clin Drug Investig; 2021 Jul; 41(7):595-604. PubMed ID: 34032988 [TBL] [Abstract][Full Text] [Related]
10. Persisting right-sided chylothorax in a patient with chronic lymphocytic leukemia: a case report. Scholz GA; Sirbu H; Semrau S; Anders K; Mackensen A; Spriewald BM J Med Case Rep; 2011 Oct; 5():492. PubMed ID: 21968097 [TBL] [Abstract][Full Text] [Related]
11. Ibrutinib discontinuation and associated factors in a real-world national sample of elderly Medicare beneficiaries with chronic lymphocytic leukemia. Huntington SF; de Nigris E; Puckett J; Kamal-Bahl S; Farooqui M; Ryland K; Sarpong E; Leng S; Yang X; Doshi JA Leuk Lymphoma; 2023 Dec; 64(14):2286-2295. PubMed ID: 37870435 [TBL] [Abstract][Full Text] [Related]
12. Cryoglobulinemic vasculitis with interruption of ibrutinib therapy for chronic lymphocytic leukemia (CLL). Wright N; Voshtina E; George G; Singavi A; Field J Int J Hematol; 2019 Dec; 110(6):751-755. PubMed ID: 31494832 [TBL] [Abstract][Full Text] [Related]
13. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study. Byrd JC; Furman RR; Coutre SE; Flinn IW; Burger JA; Blum K; Sharman JP; Wierda W; Zhao W; Heerema NA; Luan Y; Liu EA; Dean JP; O'Brien S Clin Cancer Res; 2020 Aug; 26(15):3918-3927. PubMed ID: 32209572 [TBL] [Abstract][Full Text] [Related]